OBJECTIVE: The aim of this study was to compare the efficacy and safety of telmisartan plus amlodipine with telmisartan plus hydrochlorothiazide for the treatment of uncontrolled hypertension. METHODS:Japanese hypertensive patients with uncontrolled hypertension, despite taking angiotensin II receptor blockers, were assigned randomly to either a fixed-dose combination of telmisartan/amlodipine (n=36) or telmisartan/hydrochlorothiazide (n=39). The primary endpoint was the change in office blood pressure from the baseline value at 12 weeks. RESULTS: Both telmisartan/amlodipine and telmisaratan/hydrochlorothiazide reduced the office blood pressure efficiently (systole: -25.5±12.1 vs. -24.3±15.0 mmHg, P=0.705; diastole: -10.8±13.8 vs. -11.4±12.3 mmHg, P=0.832). Treatment with telmisartan/hydrochlorothiazide resulted in the quicker onset of blood pressure-lowering effects compared with telmisartan/amlodipine. The target therapeutic blood pressure was similar in both groups at the 12-week visit. Home blood pressure measurements taken in the mornings and evenings were also similar in both groups. Compared with the telmisartan/amlodipine group, serum potassium and brain natriuretic peptide levels decreased and uric acid and hemoglobinA1c levels increased significantly in the telmisartan/hydrochlorothiazide group. Both treatment groups showed a significant reduction in urine albumin. However, the estimated glomerular filtration rate decreased slightly but significantly in the telmisartan/hydrochlorothiazide group alone. Severe adverse effects were not observed in both groups. CONCLUSION: Combination therapy with telmisartan/amlodipine or telmisartan/hydrochlorothiazide led to efficient blood pressure reduction among Japanese patients with previously uncontrolled hypertension with angiotensin II receptor blocker monotherapy.
RCT Entities:
OBJECTIVE: The aim of this study was to compare the efficacy and safety of telmisartan plus amlodipine with telmisartan plus hydrochlorothiazide for the treatment of uncontrolled hypertension. METHODS: Japanese hypertensivepatients with uncontrolled hypertension, despite taking angiotensin II receptor blockers, were assigned randomly to either a fixed-dose combination of telmisartan/amlodipine (n=36) or telmisartan/hydrochlorothiazide (n=39). The primary endpoint was the change in office blood pressure from the baseline value at 12 weeks. RESULTS: Both telmisartan/amlodipine and telmisaratan/hydrochlorothiazide reduced the office blood pressure efficiently (systole: -25.5±12.1 vs. -24.3±15.0 mmHg, P=0.705; diastole: -10.8±13.8 vs. -11.4±12.3 mmHg, P=0.832). Treatment with telmisartan/hydrochlorothiazide resulted in the quicker onset of blood pressure-lowering effects compared with telmisartan/amlodipine. The target therapeutic blood pressure was similar in both groups at the 12-week visit. Home blood pressure measurements taken in the mornings and evenings were also similar in both groups. Compared with the telmisartan/amlodipine group, serum potassium and brain natriuretic peptide levels decreased and uric acid and hemoglobin A1c levels increased significantly in the telmisartan/hydrochlorothiazide group. Both treatment groups showed a significant reduction in urine albumin. However, the estimated glomerular filtration rate decreased slightly but significantly in the telmisartan/hydrochlorothiazide group alone. Severe adverse effects were not observed in both groups. CONCLUSION: Combination therapy with telmisartan/amlodipine or telmisartan/hydrochlorothiazide led to efficient blood pressure reduction among Japanese patients with previously uncontrolled hypertension with angiotensin II receptor blocker monotherapy.